Добавил:
ivanov666
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Антифосфолипидный синдром клинико-биохимические аспекты патогенеза, диагностики и лечения. Учебно-методическое пособие
.pdf
17. Kutteh W. H. Antiphospholipid antibody-associated recurrent pregnancy
loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin
alone. Amer J Obstet Gynecol, 1996; 174 (5): 1584–1589.
18. Kutteh W. H. Antiphospholipid antibodies and reproduction. J Reprod Immunol, 1997; 35: 151–171.
19. Levy R. A. et al. Placental pathology in antiphospholipid syndrome. Lupus, 1998; 7 (Suppl 2): P. 81–85.
20. Nacinovich R. et al. Neuropsychological development of children born to
patients with antiphospholipid syndrome. Arthritis Rheum, 2008: 59 (3): 345–351.
21. Miones B. L. Update on antipospholipid syndrome in children. Rheumatol
Rep, 2011; 13(1): 86–89.
22. Goel N. et al. Familial antiphospholipid antibody syndrome: Criteria for
disease and evidence for autosomal — dominant inheritance. Arthritis Rheum,
1999; 42: 318–327.
23. Kearon C. Duration of anticoagulation for venous thromboembolism.
J Thrombosis Thrombolysis, 2001; 12: 59–65.
24. Koster T. et al. Factor VII and brinogen levels as risk factors for venous
thrombosis. A case–control study of plasma levels and DNA polymorphisms: the
Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719–722.
25. Koster T. et al. Role of clotting factor VIII in effect of von Willebrand
factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152–155.
26. Kupfermine M. et al. Inherited thrombophilia is associated with early onset preeclampsia, fetal growth restriction, fetal demise and abruptio placentae.
Soc Gynecol Invest, 1998; 5: 137A.
27. Kupferminе M. et al. Increased frequency of genetic thrombophilia in
women with сomplications of pregnancy. New Engl J Med, 1999; 340 (1): 9–13.
28. Kurosawa S. et al. Identication of functional endothelial protein C receptor in human plasma. J Clin Invest 1997; 100: 411–418.
29. Piette J.-C. et al. Antiphospholipid syndrome: Clinical and immunologic
manifestations and patterns of disease expression in a cohort of 1000 patients.
Arthritis Rheum, 2002; 46: 1019–1027.
30. Petri M. Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. Curr Rheumatol Report, 2003; 5: 370–373.
31. Vora S. K., Asherson R. A., Erkan D. Catastrophic antiphospholipid syndrome. J Int Care Med, 2006; 21: 144–159.
32. Von Landenberg P. et al. Antiphospholipid syndrome. Pathogenesis, molecular basis and clinical aspects. Med Clin, 2001; 96: 331–342.
33. Miyakis S., Lockshin M. D., Atsumi T. et al. International consensus statement on an update of the classication criteria for denite antiphospholipid syndrome (APS). J Thromb Haemost, 2006; 4 (2): 295–306.
41
34. O’Connor F. F. et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa)
as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with
unstable coronary syndromes. Blood, 2001; 98: 3256–3260.
35. Michaels L. A. A response to: laboratory testing for thrombophilia in pediatric patients. Thromb. Haemost, 2003; 89: 204–205.
36. Pengo V., Tripodi A., De Groot P. et al. Update of the guidelines for lupus
anticoagulant detection. J Thromb Haemost, 2009; 7: 1737–1740.
37. Hanly J. G. Antiphospholipid syndrome. CMAJ, 2003; 168 (13): 1675–1682.
38. Herrington D. M., Klein K. P. Effects of estrogen on thrombosis and inammation. Rev Cardiovasc Med, 2002; 3 (1): 49–56.
39. Napoleone E. et al. Angiotensin-converting enzyme inhibitors down regulate tissue factor synthesis in monocytes. Circ Res, 2000; 86: 139–143.
40. Pierangeli S., Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus, 2010; 19: 475–485.
41. Wahl D. еt al. Meta-analysis of the risk venous thrombosis in individuals
with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus, 1998; 7: 15–22.
42. Rauova L. et al. Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). J Thromb Haemost, 2009,
7 Suppl.1: 249–252.
43. Hungtincton J. A. Mechanisms of glycosaminoglycan activation of the
serpins in hemostasis. J Thromb Haemost, 2003; 7: 1535–1549.
44. Merkel N., Gunther G., Schobess R. Long-term treatment of thrombosis
with enoxaparin in pediatric and adolescent patients. Acta Haematol, 2006; 115:
230–236.
45. Miones B. L. Update on antipospholipid syndrome in children. Rheumatol
Rep, 2011; 13(1): 86–89.
ОГЛАВЛЕНИЕ
Введение .................................................................................................3
1. Структура и функции фосфолипидов .............................................. 4
2. Эпидемиология и патогенез АФС ................................................... 12
3. Клиническая картина АФС ............................................................. 18
4. Катастрофический АФС (синдром Ашерсона) ............................. 21
5. Диагностика АФС ............................................................................ 23
6. Патогенез COVID-19-индуцированного вторичного АФС .......... 31
7. Принципы терапии АФС ................................................................. 33
Список сокращений ............................................................................ 39
Список литературы ...............................................................................40
Учебное издание
Стуров Виктор Геннадьевич,
Гуляева Людмила Федоровна,
Тамкович Светлана Николаевна
АНТИФОСФОЛИПИДНЫЙ СИНДРОМ:
клинико-биохимические аспекты патогенеза,
диагностики и лечения
Учебно-методическое пособие
Редактор Н. А. Ермакова
Верстка А. С. Терешкиной
Обложка Е. В. Неклюдовой
Подписано в печать 10.07.2023 г.
Формат 60 × 84 1/16. Уч.-изд. л. 2,75. Усл. печ. л. 2,5.
Тираж 75 экз. Заказ № 84.
Издательско-полиграфический центр НГУ
630090, Новосибирск, ул. Пирогова, 2.
Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]